AdultPediatricDosage Forms & Strengths capsule 10mg 18mg 25mg 40mg 60mg 80mg 100mg Attention-Deficit/Hyperactivity Disorder Indicated for attention-deficit/hyperactivity disorder (ADHD) 40 mg PO once daily initially; increase after ≥3 days to 80 mg PO once daily or divided q12hr After 2-4 additional weeks, may increase to ≤100 mg if optimal response is not achieved No data available to support increased effectiveness at higher doses Dosage Modifications Strong CYP2D6 inhibitors or patients who are poor CYP2D6 metabolizers Poor CYP2D6 metabolizers: 0.5 mg/kg/day initially; may only increase to 1.2 mg/kg/day if symptoms fail to improve after 4 weeks and initial dose is well tolerated Coadministration with strong CYP2D6 inhibitor: 40 mg PO once daily initially; may only increase to 80 mg/day if symptoms fail to improve after 4 weeks and initial dose is well tolerated Renal impairment All severities, including end-stage renal disease: No dosage adjustment necessary Hepatic impairment Mild (Child-Pugh class A): No dosage adjustment necessary Moderate (Child-Pugh class B): Decrease initial and target dosage by 50% Severe (Child-Pugh class C): Decrease initial and target dosage by 75% Dosing Considerations Screening for bipolar disorder Before initiating, screen for personal or family history of bipolar disorder, mania, or hypomania Dosage Forms & Strengths capsule 10mg 18mg 25mg 40mg 60mg 80mg 100mg Attention-Deficit/Hyperactivity Disorder Indicated for attention-deficit/hyperactivity disorder (ADHD) ≥6 years and ≤70 kg: 0.5 mg/kg PO once daily; increase after ≥3 days to target dosage of ~1.2 mg/kg PO once daily or divided q12hr; total daily dose not to exceed 1.4 mg/kg or 100 mg, whichever is less; no benefit observed with higher doses >70 kg: 40 mg PO once daily initially; increase after ≥3 days to 80 mg PO once daily or divided q12hr; if necessary, may increase after 2-4 additional weeks to 100 mg PO once daily Treatment may be needed for extended periods of time; reevaluate long-term efficacy for individual patients Dosage Modifications Strong CYP2D6 inhibitors or patients who are poor CYP2D6 metabolizers Poor CYP2D6 metabolizers: 0.5 mg/kg/day initially; may only increase to 1.2 mg/kg/day if symptoms fail to improve after 4 weeks and initial dose is well tolerated Coadministration with strong CYP2D6 inhibitor: 40 mg PO once daily initially; may only increase to 80 mg/day if symptoms fail to improve after 4 weeks and initial dose is well tolerated Renal impairment All severities, including end-stage renal disease: No dosage adjustment necessary Hepatic impairment Mild (Child-Pugh class A): No dosage adjustment necessary Moderate (Child-Pugh class B): Decrease initial and target dosage by 50% Severe (Child-Pugh class C): Decrease initial and target dosage by 75% Dosing Considerations Screening for bipolar disorder Before initiating, screen for personal or family history of bipolar disorder, mania, or hypomania Need for comprehensive treatment program Indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) May not be indicated for all patients with this syndrome Not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis Appropriate educational placement is essential in children and adolescents with this diagnosis and psychosocial intervention is often helpful Interaction CheckerEnter a drug name and atomoxetineNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (12)cisaprideatomoxetine and cisapride both increase QTc interval. Contraindicated.dronedaroneatomoxetine and dronedarone both increase QTc interval. Contraindicated.iobenguane I 123atomoxetine decreases effects of iobenguane I 123 by receptor binding competition. Contraindicated. If clinically appropriate, discontinue drugs that compete for NE receptor sites for at least 5 half-lives; may cause false-negative imaging results.isocarboxazidisocarboxazid increases effects of atomoxetine by pharmacodynamic synergism. Contraindicated. The use of atomoxetine with monoamine oxidase inhibitors (MAOIs) is contraindicated. Risk of acute hypertensive episode.linezolidlinezolid increases effects of atomoxetine by pharmacodynamic synergism. Contraindicated. The use of atomoxetine with monoamine oxidase inhibitors (MAOIs) is contraindicated. Risk of acute hypertensive episode.phenelzinephenelzine increases effects of atomoxetine by pharmacodynamic synergism. Contraindicated. The use of atomoxetine with monoamine oxidase inhibitors (MAOIs) is contraindicated. Risk of acute hypertensive episode.procarbazineprocarbazine increases effects of atomoxetine by pharmacodynamic synergism. Contraindicated. The use of atomoxetine with monoamine oxidase inhibitors (MAOIs) is contraindicated. Risk of acute hypertensive episode.rasagilinerasagiline increases effects of atomoxetine by pharmacodynamic synergism. Contraindicated. The use of atomoxetine with monoamine oxidase inhibitors (MAOIs) is contraindicated. Risk of acute hypertensive episode.selegilineselegiline increases effects of atomoxetine by pharmacodynamic synergism. Contraindicated. The use of atomoxetine with monoamine oxidase inhibitors (MAOIs) is contraindicated. Risk of acute hypertensive episode.selegiline transdermalselegiline transdermal increases effects of atomoxetine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.thioridazineatomoxetine and thioridazine both increase QTc interval. Contraindicated.tranylcyprominetranylcypromine increases effects of atomoxetine by pharmacodynamic synergism. Contraindicated. The use of atomoxetine with monoamine oxidase inhibitors (MAOIs) is contraindicated. Risk of acute hypertensive episode.Serious - Use Alternative (78)amiodaroneatomoxetine and amiodarone both increase QTc interval. Avoid or Use Alternate Drug.amisulprideatomoxetine and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.arsenic trioxideatomoxetine and arsenic trioxide both increase QTc interval. Avoid or Use Alternate Drug.artemether/lumefantrineatomoxetine and artemether/lumefantrine both increase QTc interval. Avoid or Use Alternate Drug.asenapineatomoxetine and asenapine both increase QTc interval. Avoid or Use Alternate Drug.asenapine transdermalasenapine transdermal and atomoxetine both increase QTc interval. Avoid or Use Alternate Drug.azithromycinatomoxetine and azithromycin both increase QTc interval. Avoid or Use Alternate Drug.bedaquilineatomoxetine and bedaquiline both increase QTc interval. Avoid or Use Alternate Drug.buprenorphineatomoxetine and buprenorphine both increase QTc interval. Avoid or Use Alternate Drug.buprenorphine buccalbuprenorphine buccal and atomoxetine both increase QTc interval. Avoid or Use Alternate Drug.buprenorphine subdermal implantbuprenorphine subdermal implant and atomoxetine both increase QTc interval. Avoid or Use Alternate Drug.buprenorphine transdermalbuprenorphine transdermal and atomoxetine both increase QTc interval. Avoid or Use Alternate Drug.buprenorphine, long-acting injectionbuprenorphine, long-acting injection and atomoxetine both increase QTc interval. Avoid or Use Alternate Drug.chloroquineatomoxetine and chloroquine both increase QTc interval. Avoid or Use Alternate Drug.chlorpromazineatomoxetine and chlorpromazine both increase QTc interval. Avoid or Use Alternate Drug.clarithromycinatomoxetine and clarithromycin both increase QTc interval. Avoid or Use Alternate Drug.crizotinibatomoxetine and crizotinib both increase QTc interval. Avoid or Use Alternate Drug.dacomitinibdacomitinib will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid use with CYP2D6 substrates where minimal increases in concentration of the CYP2D6 substrate may lead to serious or life-threatening toxicities. desfluranedesflurane and atomoxetine both increase QTc interval. Avoid or Use Alternate Drug.disopyramideatomoxetine and disopyramide both increase QTc interval. Avoid or Use Alternate Drug.dofetilideatomoxetine and dofetilide both increase QTc interval. Avoid or Use Alternate Drug.droperidolatomoxetine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.encorafenibatomoxetine and encorafenib both increase QTc interval. Avoid or Use Alternate Drug.entrectinibatomoxetine and entrectinib both increase QTc interval. Avoid or Use Alternate Drug.eribulineribulin and atomoxetine both increase QTc interval. Avoid or Use Alternate Drug.erythromycin baseatomoxetine and erythromycin base both increase QTc interval. Avoid or Use Alternate Drug.erythromycin ethylsuccinateatomoxetine and erythromycin ethylsuccinate both increase QTc interval. Avoid or Use Alternate Drug.erythromycin lactobionateatomoxetine and erythromycin lactobionate both increase QTc interval. Avoid or Use Alternate Drug.erythromycin stearateatomoxetine and erythromycin stearate both increase QTc interval. Avoid or Use Alternate Drug.fexinidazolefexinidazole and atomoxetine both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels or prolong QT interval.flecainideatomoxetine and flecainide both increase QTc interval. Avoid or Use Alternate Drug.fluoxetineatomoxetine and fluoxetine both increase QTc interval. Avoid or Use Alternate Drug.foscarnetatomoxetine and foscarnet both increase QTc interval. Avoid or Use Alternate Drug.givosirangivosiran will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP2D6 substrates with givosiran. If unavoidable, decrease the CYP2D6 substrate dosage in accordance with approved product labeling.glasdegibatomoxetine and glasdegib both increase QTc interval. Avoid or Use Alternate Drug.hydroxychloroquine sulfateatomoxetine and hydroxychloroquine sulfate both increase QTc interval. Avoid or Use Alternate Drug.ibutilideatomoxetine and ibutilide both increase QTc interval. Avoid or Use Alternate Drug.iloperidoneatomoxetine and iloperidone both increase QTc interval. Avoid or Use Alternate Drug.inotuzumabatomoxetine and inotuzumab both increase QTc interval. Avoid or Use Alternate Drug.iobenguane I 131atomoxetine will decrease the level or effect of iobenguane I 131 by Other (see comment). Avoid or Use Alternate Drug. Based on the mechanism of action of iobenguane, drugs that reduce catecholamine uptake or that deplete catecholamine stores may interfere with iobenguane uptake into cells, and thus, reduce iobenguane efficacy. Discontinue interfering drugs for at least 5 half-lives before administration of either the dosimetry or an iobenguane dose. Do not administer these drugs until at least 7 days after each iobenguane dose.isofluraneatomoxetine and isoflurane both increase QTc interval. Avoid or Use Alternate Drug.ivosidenibatomoxetine and ivosidenib both decrease QTc interval. Avoid or Use Alternate Drug.lefamulinlefamulin and atomoxetine both increase QTc interval. Avoid or Use Alternate Drug.lenvatinibatomoxetine and lenvatinib both increase QTc interval. Avoid or Use Alternate Drug.lopinaviratomoxetine and lopinavir both increase QTc interval. Avoid or Use Alternate Drug.methadoneatomoxetine and methadone both increase QTc interval. Avoid or Use Alternate Drug.midostaurinatomoxetine and midostaurin both increase QTc interval. Avoid or Use Alternate Drug.nilotinibatomoxetine and nilotinib both increase QTc interval. Avoid or Use Alternate Drug.ondansetronatomoxetine and ondansetron both increase QTc interval. Avoid or Use Alternate Drug.osimertinibatomoxetine and osimertinib both increase QTc interval. Avoid or Use Alternate Drug.oxaliplatinatomoxetine and oxaliplatin both increase QTc interval. Avoid or Use Alternate Drug.ozanimodatomoxetine and ozanimod both increase QTc interval. Avoid or Use Alternate Drug.paliperidoneatomoxetine and paliperidone both increase QTc interval. Avoid or Use Alternate Drug.panobinostatatomoxetine and panobinostat both increase QTc interval. Avoid or Use Alternate Drug.pazopanibatomoxetine and pazopanib both increase QTc interval. Avoid or Use Alternate Drug.pentamidineatomoxetine and pentamidine both increase QTc interval. Avoid or Use Alternate Drug.pimavanserinatomoxetine and pimavanserin both increase QTc interval. Avoid or Use Alternate Drug.pimozideatomoxetine and pimozide both increase QTc interval. Contraindicated.pitolisantatomoxetine and pitolisant both increase QTc interval. Avoid or Use Alternate Drug.ponesimodatomoxetine and ponesimod both increase QTc interval. Avoid or Use Alternate Drug.procainamideatomoxetine and procainamide both increase QTc interval. Avoid or Use Alternate Drug.propafenoneatomoxetine and propafenone both increase QTc interval. Avoid or Use Alternate Drug.quetiapineatomoxetine and quetiapine both increase QTc interval. Avoid or Use Alternate Drug.quinidineatomoxetine and quinidine both increase QTc interval. Avoid or Use Alternate Drug.quinineatomoxetine and quinine both increase QTc interval. Avoid or Use Alternate Drug.ribociclibatomoxetine and ribociclib both increase QTc interval. Avoid or Use Alternate Drug.saquinaviratomoxetine and saquinavir both increase QTc interval. Avoid or Use Alternate Drug.selpercatinibatomoxetine and selpercatinib both increase QTc interval. Avoid or Use Alternate Drug.sevofluraneatomoxetine and sevoflurane both increase QTc interval. Avoid or Use Alternate Drug.siponimodatomoxetine and siponimod both increase QTc interval. Avoid or Use Alternate Drug.sorafenibatomoxetine and sorafenib both increase QTc interval. Avoid or Use Alternate Drug.sotalolatomoxetine and sotalol both increase QTc interval. Avoid or Use Alternate Drug.tetrabenazineatomoxetine and tetrabenazine both increase QTc interval. Avoid or Use Alternate Drug.toremifeneatomoxetine and toremifene both increase QTc interval. Avoid or Use Alternate Drug.trazodoneatomoxetine and trazodone both increase QTc interval. Avoid or Use Alternate Drug.vandetanibatomoxetine and vandetanib both increase QTc interval. Avoid or Use Alternate Drug.vemurafenibatomoxetine and vemurafenib both increase QTc interval. Avoid or Use Alternate Drug.ziprasidoneatomoxetine and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.Monitor Closely (123)abirateroneabiraterone increases levels of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Reduced initial doses of atomoxetine are recommended with strong CYP2D6 inhibitors.albuterolatomoxetine, albuterol. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Risk of tachycardia, increased blood pressure.alfuzosinatomoxetine and alfuzosin both increase QTc interval. Use Caution/Monitor.amiodaroneamiodarone will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.amitriptylineatomoxetine and amitriptyline both increase QTc interval. Use Caution/Monitor.anagrelideatomoxetine and anagrelide both increase QTc interval. Use Caution/Monitor.apomorphineatomoxetine and apomorphine both increase QTc interval. Use Caution/Monitor.arformoterolarformoterol, atomoxetine. Other (see comment). Use Caution/Monitor. Comment: Exercise caution if beta-agonists and atomoxetine are coadministered. Interaction may be less likely with inhaled beta-agonists versus those given systemically. .atomoxetine and arformoterol both increase QTc interval. Use Caution/Monitor.artemether/lumefantrineartemether/lumefantrine will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.asenapineasenapine will increase the level or effect of atomoxetine by Other (see comment). Use Caution/Monitor. Potential for enhanced CNS depression. Monitor closely during conurrent use.bupropionbupropion will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.celecoxibcelecoxib will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.chloroquinechloroquine will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.cimetidinecimetidine will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.ciprofloxacinatomoxetine